bti
BTI: Listed Venture Capital Pioneer - Liquid Gold in the Tech Rush
Updated 8 Oct 2025
BTI trades at 21% discount to $1.64 NAV despite 33% portfolio IRR. Fair value $1.61 implies 33% upside with 6% franked yield.
View noteGrowth: Positive
bfg
BFG: Financial Services Transformer - Platform Play with Fortress Balance Sheet
Updated 8 Oct 2025
Bell Financial Group trades at $1.23 versus $2.34 fair value, offering 90% upside through platform transformation with $96.8m net cash providing downside protection.
View notea1m
A1M: Copper Miner - Jericho's Make-or-Break Moment
Updated 8 Oct 2025
Development-stage copper producer with fair value A$0.289 vs current A$0.32. Binary Jericho execution risk with 70% combined failure probability creates unfavourable risk-reward for conservative investors.
View notetpw
TPW: Online Furniture Pioneer - Margin Magic or Amazon's Next Target?
Updated 8 Oct 2025
Temple & Webster fair value $7.76, EBITDA margins expanding 3.1% to 4.5% peak, 70% Amazon expansion risk, 12.8% ROIC, growth-oriented investors
View notethl
THL: RV Rental Giant - Tourism's Sleeping Beauty Awakens
Updated 8 Oct 2025
Global #1 RV rental operator trading at $2.02 vs $6.55 fair value (224% upside). Tourism recovery from 85% to 100%+ of 2019 levels drives fleet utilisation and margin expansion, though execution risks remain.
View notesxe
SXE: Infrastructure Services Transformer - Safety First, Growth Second
Updated 8 Oct 2025
BUY rating with $2.19 fair value vs $1.94 current price. 24.8% ROIC, debt-free balance sheet, 21-year safety record. Infrastructure supercycle exposure.
View notermy
RMY: PropTech Platform - Price Check Required Before Checkout
Updated 8 Oct 2025
RMA Global trades at $3.50 vs $0.170 fair value assessment. Platform transformation achieving positive cash flow with 35% revenue growth potential through US expansion. Price verification critical.
View notepyc
PYC: RNA Therapeutics Pioneer - Platform Validated, Value Undervalued
Updated 8 Oct 2025
Clinical-stage RNA therapeutics with validated platform technology trading at $1.26 versus $14.41 fair value, offering 1,044% upside potential for growth investors.
View notelov
LOV: Fast-Fashion Jewellery Giant - Margin Mirage Meets Reality Check
Updated 8 Oct 2025
Strong sell recommendation with 47% downside to $21.77 fair value. Exceptional margins unsustainable as competition intensifies.
View noteimu
IMU: Biotech Breakthrough - CAR T Revolution or Clinical Mirage?
Updated 8 Oct 2025
Clinical-stage biotechnology with 79% Phase 1b response rate trading at $0.275 versus $4.12 fair value, offering 1,371% upside through allogeneic CAR T platform advantages.
View notegyg
GYG: Mexican QSR Leader - Clean Food, Dirty Valuation
Updated 8 Oct 2025
High-quality Australian restaurant business with 45% market share trading at 35% premium to $16.22 fair value, requiring extraordinary execution to justify current pricing
View notebhp
BHP: Mining Colossus - Copper's Crown, Iron's Throne
Updated 8 Oct 2025
Fair value AUD 51.35 vs current AUD 41.96 (22% upside). Industry-leading cost position with strategic pivot to future-facing commodities. Quality score 7.76/10.
View note